S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
US7632802B2 · kind B2 · utility
6Cited by
9References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 25, 2004 |
| Grant date | Dec 15, 2009 |
| Priority date | — |
| Expiry date | Nov 7, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method and composition for inducing lymphocyte proliferation and migration, and for reducing the risks of microbial infections in patients immuno-suppressed. The present invention particularly relates to the use of S100 protein, such as MRP, to induce the proliferation, differentiation and release of immune cells from bone marrow. More particularly, S100A8, S100A9, S100A12 and S100A8/A9 are administered to patients with lowered neutrophil blood concentrations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.